Moreover, the 36-month beta value for CATX is 1.30. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CATX is 48.31M and currently, short sellers hold a 16.61% of that float. On November 14, 2024, CATX’s average trading volume was 872.83K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CATX) stock’s latest price update
Perspective Therapeutics Inc (AMEX: CATX)’s stock price has plunge by -6.94relation to previous closing price of 10.67. Nevertheless, the company has seen a -19.53% plunge in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-12 that SEATTLE, Nov. 12, 2024 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced third quarter financial results for the period ended September 30, 2024.
CATX’s Market Performance
Perspective Therapeutics Inc (CATX) has experienced a -19.53% fall in stock performance for the past week, with a -20.94% drop in the past month, and a -28.87% drop in the past quarter. The volatility ratio for the week is 6.86%, and the volatility levels for the past 30 days are at 5.81% for CATX. The simple moving average for the last 20 days is -15.75% for CATX stock, with a simple moving average of -22.54% for the last 200 days.
Analysts’ Opinion of CATX
Many brokerage firms have already submitted their reports for CATX stocks, with UBS repeating the rating for CATX by listing it as a “Buy.” The predicted price for CATX in the upcoming period, according to UBS is $20 based on the research report published on October 24, 2024 of the current year 2024.
Wedbush, on the other hand, stated in their research note that they expect to see CATX reach a price target of $25. The rating they have provided for CATX stocks is “Outperform” according to the report published on October 01st, 2024.
Truist gave a rating of “Buy” to CATX, setting the target price at $21 in the report published on September 25th of the current year.
CATX Trading at -22.59% from the 50-Day Moving Average
After a stumble in the market that brought CATX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.87% of loss for the given period.
Volatility was left at 5.81%, however, over the last 30 days, the volatility rate increased by 6.86%, as shares sank -23.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.71% lower at present.
During the last 5 trading sessions, CATX fell by -19.53%, which changed the moving average for the period of 200-days by +32.24% in comparison to the 20-day moving average, which settled at $11.79. In addition, Perspective Therapeutics Inc saw 147.01% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CATX starting from Mark Austin, who proposed sale 2,500 shares at the price of $15.80 back on Sep 12 ’24. After this action, Mark Austin now owns shares of Perspective Therapeutics Inc, valued at $39,500 using the latest closing price.
Hunt Jonathan Robert, the Chief Financial Officer of Perspective Therapeutics Inc, purchase 1,800 shares at $9.81 during a trade that took place back on Jun 17 ’24, which means that Hunt Jonathan Robert is holding 35,971 shares at $17,667 based on the most recent closing price.
Stock Fundamentals for CATX
Current profitability levels for the company are sitting at:
- -6.43 for the present operating margin
- 0.04 for the gross margin
The net margin for Perspective Therapeutics Inc stands at -6.3. The total capital return value is set at -0.21. Equity return is now at value -29.53, with -27.07 for asset returns.
Based on Perspective Therapeutics Inc (CATX), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -5.5. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -521.62.
Currently, EBITDA for the company is -14.84 million with net debt to EBITDA at 0.7. When we switch over and look at the enterprise to sales, we see a ratio of 192.1. The receivables turnover for the company is 1.97for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.60.
Conclusion
To wrap up, the performance of Perspective Therapeutics Inc (CATX) has been mixed in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
